Mankind Pharma has secured an exclusive agreement with Chongqing Chenan Biopharmaceutical. This partnership focuses on commercialising two insulin analogues for diabetes care. The deal will enhance Mankind Pharma’s injectable diabetes segment offerings. These new products will strengthen the company’s comprehensive patient portfolio.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.